CARIS LIFE SCIENCES, INC. vs RadNet, Inc., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Neither company's growth appears in these columns, but the models tell you where it lives: Caris grows by adding molecular tests to a menu, software-like economics arriving slowly (2.4% operating margin, a 7.05 current ratio of IPO cash), while RadNet grows by adding imaging centers, real-estate economics that never fatten (negative 0.7% net margin, 0.82 turns of debt). RadNet's 7.2% free-cash yield is depreciation accounting handing back what the income statement hides; Caris yields little but holds the cleaner sheet. Caris trades at 52.9 times thin earnings; RadNet has none to price. Two diagnostics tickers, one selling chemistry, one selling square footage; the margins will never meet.
Comparison updated 2026-07-10.
| Metric | CAI | RDNT |
|---|---|---|
| Price | $18.52 | $60.71 |
| Market cap | $5.2B | $4.7B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/E | 52.9 | — |
| P/B | 8.82 | 3.46 |
| P/S | 5.77 | 2.18 |
| EV/EBITDA | 37.2 | 23.8 |
| Revenue growth | +91.2% | +14.7% |
| Operating margin | 2.4% | -4.2% |
| Net margin | 3.8% | -0.7% |
| Return on equity | 5.7% | -1.1% |
| Return on assets | 2.9% | -0.4% |
| Return on invested capital | 8.8% | 2.0% |
| FCF yield | 2.4% | 7.2% |
| Debt / equity | 0.64 | 0.82 |
| Current ratio | 7.05 | 1.17 |
| Altman Z (solvency) | 4.14 | 1.63 |
| Piotroski F (quality) | 5 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.